<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27035" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pernio</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Whitman</surname>
            <given-names>Patrick A.</given-names>
          </name>
          <aff>Sampson Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Crane</surname>
            <given-names>Jonathan S.</given-names>
          </name>
          <aff>Sampson Regional Med Ctr / Campbell Univ</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Patrick Whitman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jonathan Crane declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27035.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Pernio also referred to as chilblains, is a rare inflammatory condition. The term "chilblains" derives from two Old English words "chill" (cold) and "blegen" (sore). Most commonly, pernio affects acral skin and primarily results as a response to cold, damp conditions. It is typically idiopathic and acute; however, chronic forms have been identified. This activity outlines the evaluation and management of chilblains (pernio) and reviews the role of the healthcare team in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the risk factors for developing chilblains/pernio.</p></list-item><list-item><p>Describe the common physical exam findings of a patient presenting with pernio.</p></list-item><list-item><p>Summarize the management of a patient presenting with chilblains.</p></list-item><list-item><p>Explain the importance of collaboration and communication amongst the interprofessional team to improve outcomes for patients affected by chilblains.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27035&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27035">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27035.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Pernio, also referred to as chilblains, is a rare inflammatory condition. Chilblains derives from two Old English words "chill" ( cold ) and "blegen" (sore). Most commonly, pernio affects acral skin and primarily results as a&#x000a0;response to cold, damp conditions. It is typically idiopathic and acute; however, chronic forms also exist.&#x000a0;</p>
        <p>Secondary pernio has associations with other conditions--the most common being the association with systemic lupus erythematosus (chilblain lupus erythematosus or CHLE). As a result, even though most pernio cases are idiopathic, the presentation of pernio should prompt the provider to screen for some of the more common secondary conditions known to trigger pernio.&#x000a0;</p>
        <p>Epidemiologically, pernio typically affects women more often than men and is more common among people residing in cold climates.&#x000a0;</p>
        <p>The diagnosis is largely clinical and based on a thorough history and physical exam. Biopsies are not a recommendation as the histopathologic findings are non-specific.&#x000a0;</p>
        <p>Treatment often focuses on prevention. Avoidance of the cold is vital in the prevention of development of the lesions, and several medications, most commonly nifedipine and other calcium channel blockers, have been implicated in aiding in the&#x000a0;resolution of existing lesions.</p>
        <p>Overall, the prognosis of pernio is good with minimal&#x000a0;chronic sequelae.&#x000a0;</p>
      </sec>
      <sec id="article-27035.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Pernio is mostly thought to be idiopathic; however, while several forms of secondary pernio exist, they are incredibly rare, and the direct association has not clinically correlated with extensive studies due to the rarity. The most common form of secondary pernio is the association with systemic lupus erythematosus and the subsequent development of chilblain lupus erythematosus (CHLE).<xref ref-type="bibr" rid="article-27035.r1">[1]</xref></p>
        <p>Of note, research has found pernio as the presenting symptom of a blast crisis in&#x000a0;patients diagnosed with acute lymphoblastic leukemia.<xref ref-type="bibr" rid="article-27035.r2">[2]</xref></p>
      </sec>
      <sec id="article-27035.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Pernio&#x000a0;has generally been found to affect women&#x000a0;more often&#x000a0;than men. The most significant risk factor appears to be exposure to cold, damp climates, and pernio is often prevalent in areas without central heating such as many parts of the UK and northern Europe. Due to pernio's association with the cold and damp, the presentation can be found to be seasonal, with an increase in prevalence during the winter months and relapse occurring when the weather warms again in the spring.<xref ref-type="bibr" rid="article-27035.r3">[3]</xref><xref ref-type="bibr" rid="article-27035.r4">[4]</xref></p>
      </sec>
      <sec id="article-27035.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology and pathogenesis of pernio remain&#x000a0;still largely unknown due to the rarity of the condition. However, the thinking is that there is some association with vasospasm as the primary pathophysiologic finding, particularly when the patient becomes exposed to cold, damp conditions for a prolonged period. In a small study by the Mayo Clinic, researchers exposed five patients with known pernio to ice-water immersions and analyzed the patients'&#x000a0;vascular response. They found that all of the patients demonstrated vasospasm when exposed to the ice water bath, potentially&#x000a0;discovering a target for pharmacologic therapy in patients with pernio.<xref ref-type="bibr" rid="article-27035.r5">[5]</xref></p>
      </sec>
      <sec id="article-27035.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Unfortunately, the histological reports of confirmed pernio are few and far between, making consistent histologic diagnosis challenging and largely nonspecific. However, the most commonly reported findings in pernio include dermal infiltrate with associated edema. Additionally, other findings include spongiosis, deep peri-eccrine inflammation, basal layer vacuolation, and necrotic keratinocytes within the epidermis.<xref ref-type="bibr" rid="article-27035.r3">[3]</xref><xref ref-type="bibr" rid="article-27035.r6">[6]</xref><xref ref-type="bibr" rid="article-27035.r7">[7]</xref></p>
      </sec>
      <sec id="article-27035.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Pernio&#x000a0;commonly presents as multiple erythrocyanotic lesions, typically macules, papules, or nodules that develop in response to exposure to cold, damp environments. These lesions are generally symmetric, affecting bilateral hands or feet, particularly targeting the toes and fingers. Pernio has also been reported to affect&#x000a0;other body sites with less frequency. Pernio lesions commonly appear within 24 hours of exposure to cold and will often resolve within a few weeks.<xref ref-type="bibr" rid="article-27035.r8">[8]</xref>&#x000a0;Lesions can blister or ulcerate, and patients often report symptoms of burning, tenderness, or pruritus. There have also been reports of nail dystrophy in patients with pernio after experiencing prolonged exposure to cold, damp conditions.<xref ref-type="bibr" rid="article-27035.r9">[9]</xref></p>
        <p>A worrisome potential complication is the development of a secondary infection. In patients who experience blisters or ulceration associated with pernio, as with any disease process where there is an entry point for bacteria due to skin breakdown, secondary infection can easily occur, making it increasingly necessary to treat these patients and encourage rapid resolution of blisters or ulcerations.&#x000a0;</p>
      </sec>
      <sec id="article-27035.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>A thorough history and physical exam are crucial for evaluating and diagnosing pernio. In general, asking questions regarding the timing of lesions, recent exposures to cold, and improvement of symptoms with removal of cold exposure help narrow the differential to pernio or at least one of the other vasospastic disease processes.</p>
        <p>As mentioned earlier, skin biopsies are often not helpful in the diagnosis of pernio as the histologic findings are&#x000a0;commonly non-specific. However, histologic findings of&#x000a0;lymphocytic&#x000a0;infiltrate, dermal edema, and necrotic keratinocytes can support a diagnosis of pernio.&#x000a0;</p>
        <p>Some basic lab work can help in the initial evaluation of pernio, including a complete blood count, antinuclear antibody, and serum protein electrophoresis. Depending on the presentation and precipitating factors, serum cryoglobulins are also an option if deemed appropriate. Because cryoglobulins are only rarely associated with pernio, they are often excluded from initial testing and only included after performing an initial workup.<xref ref-type="bibr" rid="article-27035.r3">[3]</xref><xref ref-type="bibr" rid="article-27035.r6">[6]</xref><xref ref-type="bibr" rid="article-27035.r7">[7]</xref><xref ref-type="bibr" rid="article-27035.r10">[10]</xref><xref ref-type="bibr" rid="article-27035.r11">[11]</xref></p>
      </sec>
      <sec id="article-27035.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Initial&#x000a0;management should focus on removing the cold insult from the patient and having the patient avoiding cold exposure. Patients should be instructed to keep gloves or socks readily available in case of cold exposure. Additionally, lifestyle&#x000a0;modifications, including smoking cessation, are recommendations due to the association with vasospasm, which can exacerbate pernio symptoms.</p>
        <p>Following initial management, second-line therapy&#x000a0;can include topical, medium to high dose corticosteroids as well as nifedipine. Clinical data is conflicting on the efficacy of topical corticosteroids in the resolution of pernio lesions. As with all topical corticosteroid therapy, patients should avoid excessive and extensive use due to the increased likelihood of tissue atrophy that is associated with long-term topical corticosteroid use.</p>
        <p>Nifedipine, a calcium channel blocker, has potentially been found to be useful as a treatment of pernio due to its vasodilatory effects, and in some small studies showed efficacy in reversing pernio lesions and even prevented further lesions from developing.<xref ref-type="bibr" rid="article-27035.r10">[10]</xref><xref ref-type="bibr" rid="article-27035.r12">[12]</xref><xref ref-type="bibr" rid="article-27035.r13">[13]</xref><xref ref-type="bibr" rid="article-27035.r14">[14]</xref></p>
      </sec>
      <sec id="article-27035.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The primary disorder that merits consideration when diagnosing pernio is chilblain lupus erythematosus (CHLE).&#x000a0;CHLE is a rare dermatology condition often confused with other forms of pernio or vasculitic processes. Due to the implications of familial genetic inheritance and the possible association with systemic lupus erythematosus, a specific diagnosis of chilblains lupus becomes a priority when a patient presents with pernio-like symptoms. CHLE is largely idiopathic, but familial variants are associated with several different genetic mutations, including <italic toggle="yes">TREX1, SAMHD1</italic>, and <italic toggle="yes">STING</italic>. Treatment is often symptomatic with steroids, but literature has shown the possibility for systemic medications such as JAK inhibitors as effective treatments. &#x000a0;While the progression to systemic lupus erythematosus (SLE) is low in CHLE, further workup is the recommended course due to the implications of long-term undiagnosed SLE.<xref ref-type="bibr" rid="article-27035.r15">[15]</xref><xref ref-type="bibr" rid="article-27035.r16">[16]</xref><xref ref-type="bibr" rid="article-27035.r17">[17]</xref></p>
        <p>Other conditions, particularly vasospastic conditions, that the clinician should consider in the differential include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Raynaud phenomenon</p>
          </list-item>
          <list-item>
            <p>Acrocyanosis</p>
          </list-item>
          <list-item>
            <p>Cryoglobulinemia</p>
          </list-item>
          <list-item>
            <p>Cold panniculitis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27035.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of pernio is overall excellent since lesions are rarely severe, and most cases of pernio can be resolved relatively easily without prolonged sequelae. In patients who develop pernio in association with chronic systemic conditions like CHLE, ensuring adequate control of the systemic illness along with symptomatic treatment of the pernio can aid in the rapid resolution of the pernio lesions.</p>
      </sec>
      <sec id="article-27035.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of pernio are similar to other vasospastic conditions, which can include tissue necrosis if vasospasm is prolonged. Additionally, with tissue breakdown and openings in the skin, providers and patients should look for any signs and symptoms of infection.&#x000a0;</p>
      </sec>
      <sec id="article-27035.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should receive education regarding the pathogenesis and development of pernio lesions and how to effectively prevent outbreaks. Education should focus on prevention by avoiding the cold and ensuring that the patient uses insulated clothing, gloves, and socks to prevent unexpected exposure to cold environments.&#x000a0;</p>
      </sec>
      <sec id="article-27035.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Pernio has many causes and requires management from an interprofessional team. Pernio caused by exposure to cold is best managed by the primary care provider or the emergency department.</p>
        <p>Overall, coordination of care is mostly between the provider and the patient. The key to pernio is patient education. Patients should be told to dress appropriately in cold weather and discontinue smoking.&#x000a0;</p>
        <p>However, if secondary pernio is thought to be the diagnosis, particularly in association with systemic lupus erythematosus, coordinated care between the primary care physician, dermatologist, and rheumatologist can significantly aid in the treatment of both the pernio and the SLE or CHLE. For secondary causes of pernio, a wound care nurse should have involvement as recurrences are common. The protection of the underlying tissues is vital. The wound care nurse should communicate with the specialist to ensure that the patient is receiving the optimal treatment for the secondary disorder responsible for pernio. Interprofessional coordination between nursing and clinicians will result in better outcomes. [Level 5]</p>
      </sec>
      <sec id="article-27035.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27035&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27035">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/pernio-chilblains/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27035">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27035/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27035">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-27035.s16">
        <fig id="article-27035.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Chilblains <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="chilblains" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27035.s17">
        <fig id="article-27035.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Pernio (chillblains) Image courtesy O.Chaigasame</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pernio" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-27035.s18">
        <title>References</title>
        <ref id="article-27035.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hedrich</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Fiebig</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hauck</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Sallmann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pfeiffer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Heubner</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lee-Kirsch</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Gahr</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Chilblain lupus erythematosus--a review of literature.</article-title>
            <source>Clin Rheumatol</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>27</volume>
            <issue>8</issue>
            <fpage>949</fpage>
            <page-range>949-54</page-range>
            <pub-id pub-id-type="pmid">18543054</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27035.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Tayebi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Uihlein</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Speiser</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gerami</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mancini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Pernio as the presenting sign of blast crisis in acute lymphoblastic leukemia.</article-title>
            <source>Pediatr Dermatol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>e74</fpage>
            <page-range>e74-e75</page-range>
            <pub-id pub-id-type="pmid">29231259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27035.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cribier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Djeridi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Peltre</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Grosshans</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>A histologic and immunohistochemical study of chilblains.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2001</year>
            <month>Dec</month>
            <volume>45</volume>
            <issue>6</issue>
            <fpage>924</fpage>
            <page-range>924-9</page-range>
            <pub-id pub-id-type="pmid">11712041</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27035.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parlette</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Parlette</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Erythrocyanotic discoloration of the toes.</article-title>
            <source>Cutis</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>65</volume>
            <issue>4</issue>
            <fpage>223</fpage>
            <page-range>223-4, 226</page-range>
            <pub-id pub-id-type="pmid">10795083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27035.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shahi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Wetter</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Cappel</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Spittell</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Vasospasm Is a Consistent Finding in Pernio (Chilblains) and a Possible Clue to Pathogenesis.</article-title>
            <source>Dermatology</source>
            <year>2015</year>
            <volume>231</volume>
            <issue>3</issue>
            <fpage>274</fpage>
            <page-range>274-9</page-range>
            <pub-id pub-id-type="pmid">26278705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27035.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boada</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bielsa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Figueras</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Ferr&#x000e1;ndiz</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Perniosis: clinical and histopathological analysis.</article-title>
            <source>Am J Dermatopathol</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-23</page-range>
            <pub-id pub-id-type="pmid">20098080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27035.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crowson</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Magro</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Idiopathic perniosis and its mimics: a clinical and histological study of 38 cases.</article-title>
            <source>Hum Pathol</source>
            <year>1997</year>
            <month>Apr</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>478</fpage>
            <page-range>478-84</page-range>
            <pub-id pub-id-type="pmid">9104949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27035.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takci</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Vahaboglu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Eksioglu</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Epidemiological patterns of perniosis, and its association with systemic disorder.</article-title>
            <source>Clin Exp Dermatol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>37</volume>
            <issue>8</issue>
            <fpage>844</fpage>
            <page-range>844-9</page-range>
            <pub-id pub-id-type="pmid">23082992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27035.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozuguz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kacar</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Karaca</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Does pernio cause nail dystrophy?</article-title>
            <source>J Pak Med Assoc</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>64</volume>
            <issue>3</issue>
            <fpage>349</fpage>
            <page-range>349-50</page-range>
            <pub-id pub-id-type="pmid">24864616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27035.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cappel</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Wetter</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Clinical characteristics, etiologic associations, laboratory findings, treatment, and proposal of diagnostic criteria of pernio (chilblains) in a series of 104 patients at Mayo Clinic, 2000 to 2011.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>89</volume>
            <issue>2</issue>
            <fpage>207</fpage>
            <page-range>207-15</page-range>
            <pub-id pub-id-type="pmid">24485134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27035.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>English</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Adult perniosis and cryoglobulinemia: a retrospective study and review of the literature.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>62</volume>
            <issue>6</issue>
            <fpage>e21</fpage>
            <page-range>e21-2</page-range>
            <pub-id pub-id-type="pmid">20466166</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27035.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ganor</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Corticosteroid therapy for pernio.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1983</year>
            <month>Jan</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>136</fpage>
            <pub-id pub-id-type="pmid">6826802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27035.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rustin</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Newton</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Dowd</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>The treatment of chilblains with nifedipine: the results of a pilot study, a double-blind placebo-controlled randomized study and a long-term open trial.</article-title>
            <source>Br J Dermatol</source>
            <year>1989</year>
            <month>Feb</month>
            <volume>120</volume>
            <issue>2</issue>
            <fpage>267</fpage>
            <page-range>267-75</page-range>
            <pub-id pub-id-type="pmid">2647123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27035.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dowd</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Rustin</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Lanigan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Nifedipine in the treatment of chilblains.</article-title>
            <source>Br Med J (Clin Res Ed)</source>
            <year>1986</year>
            <month>Oct</month>
            <day>11</day>
            <volume>293</volume>
            <issue>6552</issue>
            <fpage>923</fpage>
            <page-range>923-4</page-range>
            <pub-id pub-id-type="pmid">3094717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27035.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000fc;nther</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hillebrand</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brunk</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee-Kirsch</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Systemic involvement in TREX1-associated familial chilblain lupus.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>69</volume>
            <issue>4</issue>
            <fpage>e179</fpage>
            <page-range>e179-81</page-range>
            <pub-id pub-id-type="pmid">24034389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27035.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tao</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Leng</surname>
                <given-names>RX</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>DQ</given-names>
              </name>
            </person-group>
            <article-title>TREX1 As a Potential Therapeutic Target for Autoimmune and Inflammatory Diseases.</article-title>
            <source>Curr Pharm Des</source>
            <year>2019</year>
            <volume>25</volume>
            <issue>30</issue>
            <fpage>3239</fpage>
            <page-range>3239-3247</page-range>
            <pub-id pub-id-type="pmid">31475890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27035.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>K&#x000f6;nig</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fiehn</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schuster</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cura Costa</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>T&#x000fc;ngler</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Alvarez</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Chara</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Engel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Goldbach-Mansky</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>G&#x000fc;nther</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lee-Kirsch</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Familial chilblain lupus due to a gain-of-function mutation in STING.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>76</volume>
            <issue>2</issue>
            <fpage>468</fpage>
            <page-range>468-472</page-range>
            <pub-id pub-id-type="pmid">27566796</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
